AAAAAA

   
Results: 1-11 |
Results: 11
Pharmacodynamic characterization of the interaction between abciximab or tirofiban with unfractionated or a low molecular weight heparin in healthy subjects
Authors: Klinkhardt, U Graff, J Westrup, D Kirchmaier, CM Esslinger, HU Breddin, HK Harder, S
Citation: U. Klinkhardt et al., Pharmacodynamic characterization of the interaction between abciximab or tirofiban with unfractionated or a low molecular weight heparin in healthy subjects, BR J CL PH, 52(3), 2001, pp. 297-305
Platelet CD62 expression and PDCFAB secretion in patients undergoing PTCA and treatment with abciximab
Authors: Graff, J Andries, D Elsner, M Westrup, D Bassus, S Franz, N Klinkhardt, U Harder, S
Citation: J. Graff et al., Platelet CD62 expression and PDCFAB secretion in patients undergoing PTCA and treatment with abciximab, BR J CL PH, 51(6), 2001, pp. 577-582
Angiotensin II infusion increases plasma erythropoietin levels via an angiotensin II type 1 receptor-dependent pathway
Authors: Gossmann, J Burkhardt, R Harder, S Lenz, T Sedlmeyer, A Klinkhardt, U Geiger, H Scheuermann, EH
Citation: J. Gossmann et al., Angiotensin II infusion increases plasma erythropoietin levels via an angiotensin II type 1 receptor-dependent pathway, KIDNEY INT, 60(1), 2001, pp. 83-86
In vitro dose response to different GPIIb/IIIa-antagonists: Inter-laboratory comparison of various platelet function tests
Authors: Harder, S Klinkhardt, U Graff, J Westrup, D Kirchmaier, CM Glusa, E Mascelli, MA Marciniak, SJ Just, A Losche, W Breddin, HK
Citation: S. Harder et al., In vitro dose response to different GPIIb/IIIa-antagonists: Inter-laboratory comparison of various platelet function tests, THROMB RES, 102(1), 2001, pp. 39-48
Dose-response relationship: relevance for clinical use
Authors: Klinkhardt, U Harder, S
Citation: U. Klinkhardt et S. Harder, Dose-response relationship: relevance for clinical use, MED KLIN, 95, 2000, pp. 9-14
Interaction between the LMWH reviparin and aspirin in healthy volunteers
Authors: Klinkhardt, U Breddin, HK Esslinger, HU Haas, S Kalatzis, A Harder, S
Citation: U. Klinkhardt et al., Interaction between the LMWH reviparin and aspirin in healthy volunteers, BR J CL PH, 49(4), 2000, pp. 337-341
Thrombolytics - Drug interactions of clinical significance
Authors: Harder, S Klinkhardt, U
Citation: S. Harder et U. Klinkhardt, Thrombolytics - Drug interactions of clinical significance, DRUG SAFETY, 23(5), 2000, pp. 391-399
Differential in vitro effects of the platelet glycoprotein IIb/IIIa inhibitors abixicimab or SR121566A on platelet aggregation, fibrinogen binding and platelet secretory parameters
Authors: Klinkhardt, U Kirchmaier, CM Westrup, D Breddin, HK Mahnel, R Graff, J Hild, M Harder, S
Citation: U. Klinkhardt et al., Differential in vitro effects of the platelet glycoprotein IIb/IIIa inhibitors abixicimab or SR121566A on platelet aggregation, fibrinogen binding and platelet secretory parameters, THROMB RES, 97(4), 2000, pp. 201-207
Effect of angiotensin II infusion with and without angiotensin II type 1 receptor blockade on nitric oxide metabolism and endothelin in human beings:A placebo-controlled study in healthy volunteers
Authors: Gossmann, J Bunkhardt, R Harder, S Lenz, T Sedlmeyer, A Klinkhardt, U Haak, T Geiger, H Scheuermann, EH
Citation: J. Gossmann et al., Effect of angiotensin II infusion with and without angiotensin II type 1 receptor blockade on nitric oxide metabolism and endothelin in human beings:A placebo-controlled study in healthy volunteers, CLIN PHARM, 68(5), 2000, pp. 501-509
Ex vivo-in vitro interaction between aspirin, clopidogrel, and the glycoprotein IIb/IIIa inhibitors abciximab and SR121566A
Authors: Klinkhardt, U Kirchmaier, CM Westrup, D Graff, J Mahnel, R Breddin, HK Harder, S
Citation: U. Klinkhardt et al., Ex vivo-in vitro interaction between aspirin, clopidogrel, and the glycoprotein IIb/IIIa inhibitors abciximab and SR121566A, CLIN PHARM, 67(3), 2000, pp. 305-313
Dose-response relationship: Relevance for clinical use
Authors: Klinkhardt, U Harder, S
Citation: U. Klinkhardt et S. Harder, Dose-response relationship: Relevance for clinical use, MED KLIN, 93(12), 1998, pp. 744-749
Risultati: 1-11 |